ES416478A1 - Oral compositions for plaque caries and calculus retardation with reduced staining tendencies - Google Patents

Oral compositions for plaque caries and calculus retardation with reduced staining tendencies

Info

Publication number
ES416478A1
ES416478A1 ES416478A ES416478A ES416478A1 ES 416478 A1 ES416478 A1 ES 416478A1 ES 416478 A ES416478 A ES 416478A ES 416478 A ES416478 A ES 416478A ES 416478 A1 ES416478 A1 ES 416478A1
Authority
ES
Spain
Prior art keywords
carbon atoms
hydrogen
see formula
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES416478A
Other languages
Spanish (es)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Publication of ES416478A1 publication Critical patent/ES416478A1/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41Amines
    • A61K8/416Quaternary ammonium compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/43Guanidines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Dental Preparations (AREA)

Abstract

Procedure for preparing compositions effective in inhibiting plaque formation, caries and stones, characterized in that it comprises reacting, at a pH of 4 to 9 (A) of approximately 0.01 to 2.5% by weight of the composition of a bis-biguanide compound with the generic formula: **(See formula)** wherein A and A'each represent a phenyl radical, which may contain as a substituent up to two alkyl or alkoxy groups containing from about 1 to 4 carbon atoms, a nitro group or a halogen atom; an alkyl group containing from about 1 to 12 carbon atoms; or alicyclic groups containing from 4 to 12 carbon atoms approximately; wherein X and X'each represent an alkylene radical containing 1 to 3 carbon atoms; where z and z'can each be 0 or 1; wherein R and R'each represent hydrogen, an alkyl radical containing from about 1 to 12 carbon atoms, or an aralkyl radical containing from about 7 to 12 carbon atoms; where n is an integer from 2 to 12, inclusive; and in which the polymethylene (CH2) n chain can be interrupted with a maximum of 5 halves of ether, thioether, phenyl, or naphthyl; or its pharmaceutically acceptable salts; with (B) a quantity of a compound inhibitor of the formation of stones soluble in water and containing phosphorous selected from the group consisting of: **(See formula)** wherein R1 and R2 are hydrogen or CH2OH; n is an integer from 3 to 10; R3 is hydrogen, alkyl containing from about 1 to 20 carbon atoms, alkenyl containing from about 2 to 20 carbon atoms, phenyl, naphthyl, phenylethenyl, benzyl, halogen, amino, dimethylamino, diethylamino, N-hydroxy-N-ethylamine, acetylamino, -CH2COOH, -CH2PO3H2, -CH (PO3H2) (OH) or -CH2CH (PO3H2) 2; and R4 is hydrogen, lower alkyl, amino, benzyl, halogen, hydroxyl, -CH2COOH, -CH2PO3H2, or -CH2CH2PO3H2; **(See formula)** wherein R5, R6, R7, R8, R9 and R10 are each hydrogen or lower alkyl; **(See formula)** where n is an integer from 3 to 9; **(See formula)** where X and Y are each hydrogen or hydroxy; or a pharmaceutically acceptable salt thereof; or the condensation products of ammonia and phosphorous pentoxide, which comprises the compounds: **(See formula)** such being the amount of said compound that inhibits the formation of stones soluble in water and containing phosphorus that provides from 0.01 to 10% by weight of the composition of said anti-stone compound above that which reacts with said bis-biguanide compound. (Machine-translation by Google Translate, not legally binding)
ES416478A 1972-06-30 1973-06-30 Oral compositions for plaque caries and calculus retardation with reduced staining tendencies Expired ES416478A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26781672A 1972-06-30 1972-06-30
US33847273A 1973-03-06 1973-03-06

Publications (1)

Publication Number Publication Date
ES416478A1 true ES416478A1 (en) 1976-06-01

Family

ID=26952666

Family Applications (1)

Application Number Title Priority Date Filing Date
ES416478A Expired ES416478A1 (en) 1972-06-30 1973-06-30 Oral compositions for plaque caries and calculus retardation with reduced staining tendencies

Country Status (13)

Country Link
JP (1) JPS4966838A (en)
AT (1) AT333969B (en)
AU (1) AU474403B2 (en)
CA (1) CA1001554A (en)
CH (1) CH595100A5 (en)
DE (1) DE2332383A1 (en)
DK (1) DK135789B (en)
ES (1) ES416478A1 (en)
FR (1) FR2190459B1 (en)
GB (1) GB1432487A (en)
IE (1) IE37842B1 (en)
NL (1) NL7309090A (en)
SE (1) SE403963B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1458476A (en) * 1975-06-23 1977-12-08 Procter & Gamble Bis-biguanide compounds
SE431285B (en) * 1976-08-16 1984-01-30 Colgate Palmolive Co MUNVARDS COMPOSITION CONTAINING A PHOSPHONE SOCIETY, FOR REDUCING MISSING DIFFERENCE PICTURED BY AN INCLUDING NITROGEN ANTIBACTERIAL PLAQUE
JPS5840523B2 (en) * 1976-08-26 1983-09-06 松風陶歯製造株式会社 Dental primer composition
IT1201087B (en) * 1982-04-15 1989-01-27 Gentili Ist Spa PHARMACOLOGICALLY ACTIVE BIPPHOSPHONES, PROCEDURE FOR THEIR PREPARATION AND RELATED PHARMACEUTICAL COMPOSITIONS
US4961923A (en) * 1988-02-19 1990-10-09 Dentsply Management Corp. Irrigants for use in scaling and/or lavage apparatus
US6190642B1 (en) 1988-02-19 2001-02-20 Dentsply Research & Development Corp. Irrigating and lavage compositions
US5438076A (en) * 1988-05-03 1995-08-01 Perio Products, Ltd. Liquid polymer composition, and method of use
US6214320B1 (en) 1990-10-09 2001-04-10 Colgate-Palmolive Company Oral compositions containing anticalculus and antiplaque agents
EP3100716B1 (en) 2008-02-08 2018-09-26 Colgate-Palmolive Company Novel salts and their uses
MX361642B (en) 2013-09-13 2018-12-13 3M Innovative Properties Co Cationic antiseptic compositions.
CN111138660B (en) * 2019-12-20 2020-12-08 浙江大学 Preparation method of fluorinated polyhexamethylene biguanide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR6568736D0 (en) * 1964-04-09 1973-08-14 Drug Inc Sterling PROCESS TO PREPARE A BISGUANIDE
IT1002501B (en) * 1965-05-03 1976-05-20 Colgate Palmolive Co TOOTHPASTE COMPOSITIONS
BE722631A (en) * 1965-12-08 1969-04-21
US3639569A (en) * 1968-02-19 1972-02-01 Procter & Gamble Oral compositions for calculus retardation
US3562385A (en) * 1968-12-23 1971-02-09 Merck & Co Inc Dental antiplaque and anticalculus compositions
BE730888A (en) * 1969-04-01 1969-09-15

Also Published As

Publication number Publication date
IE37842L (en) 1973-12-30
ATA575373A (en) 1976-04-15
AU474403B2 (en) 1976-07-22
JPS4966838A (en) 1974-06-28
CH595100A5 (en) 1978-01-31
GB1432487A (en) 1976-04-14
DK135789C (en) 1977-11-28
DE2332383A1 (en) 1974-01-10
CA1001554A (en) 1976-12-14
IE37842B1 (en) 1977-10-26
DK135789B (en) 1977-06-27
FR2190459B1 (en) 1977-04-15
NL7309090A (en) 1974-01-02
AU5745173A (en) 1975-01-09
FR2190459A1 (en) 1974-02-01
AT333969B (en) 1976-12-27
SE403963B (en) 1978-09-18

Similar Documents

Publication Publication Date Title
ES416478A1 (en) Oral compositions for plaque caries and calculus retardation with reduced staining tendencies
GB1263934A (en) Oral compositions for calculus retardation
JPS55127384A (en) Novel chromone compound*its manufacture and drug composition containing it
DK151883C (en) 2- OR 3-ALKYL-SUBSTITUTED N-HYDROXYALKYL MORPHOLINES AND PREPARATIONS CONTAINING THEM
GB1448942A (en) Compositions for radiographic scanning
GB1501827A (en) Composition for use in the production of 99m technetium radio-diagnostics
IE43139L (en) Bis-biguanide compounds
GB1507846A (en) Oral compositions for plaque caries and calculus retardation with reduced staining tendencies
ES423959A1 (en) Oral compositions for plaque caries and calculus retardation with reduced staining tendencies
NZ218359A (en) Pyridine derivatives and pharmaceutical compositions
GB1419692A (en)
ES2004809A6 (en) 1-[2-(Phenylmethyl)phenyl]-piperazine compounds, a process for preparing them and pharmaceutical compostions containing them.
ES2007052A6 (en) 1,1,2-triaryl-1-butene derivatives.
HUP0303828A2 (en) Cdc25 phosphatase inhibitors, process for their preparation and their use for preparation of pharmaceutical compositions
ATE78032T1 (en) 2-PYRIDYLACETIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
ES420634A1 (en) Preparation of 2,5-disubstituted benzamides
GB1421064A (en) Oral compositions for calculus retardation
MXPA04002474A (en) Inhibition of exoprotein production using aromatic compositions.
GB1453667A (en) Radionuclide-labelled phosphonic acids for the treatment of calcific tumours
ES8203328A1 (en) 6-Fluorodihydroxyphenylalanines, a process for preparing and a pharmaceutical composition containing the same.
ES443559A1 (en) Derivatives of n-phenyl-n-aroylalanine and herbicidal compositions containing them
GB1289004A (en)
ES8303381A1 (en) 2-(Substituted phenyl)-1,3-perhydrothiazine-4-ones for treating peptic ulcers.
ES8202558A1 (en) A procedure to prepare new compounds of cefem (Machine-translation by Google Translate, not legally binding)
ES374620A1 (en) Substituted hydroxyethylglycine compounds